Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gini F Fleming

Showing results (21-30 of 180) with videos related to

Pageof 18
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 18, 2018
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastimJennifer M Collins, Gini F Fleming, Trevor N Christ
Gynecologic Oncology|March 30, 2010
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignanciesSarah M Temkin, S Diane Yamada, Gini F Fleming
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2022
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast CancerBarbara Pistilli, Caroline Lohrisch, Jori Sheade, et al.
Gynecologic Oncology|September 10, 2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group studyM Dwight Chen, Gini F Fleming, Suann Mitchell, et al.
Gynecologic Oncology|April 22, 2006
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group studyDeborah K Armstrong, Gini F Fleming, Maurie Markman, et al.
Gynecologic Oncology|July 10, 2020
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerationsKatherine C Kurnit, Pankti Reid, John W Moroney, et al.
Gynecologic Oncology|November 12, 2015
Chemotherapy-induced peripheral neuropathy: Current status and progressJamie R Brewer, Gladys Morrison, M Eileen Dolan, et al.
The Lancet. Oncology|December 3, 2005
Rare uterine cancersSheetal Acharya, Martee L Hensley, Anthony C Montag, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyDiane R Mould, Gini F Fleming, Kathleen M Darcy, et al.
Frontiers in Oncology|August 11, 2015
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case ReportDavid J VanderWeele, Gladell P Paner, Gini F Fleming, et al.
Pageof 18

Showing results (21-30 of 180) with videos related to

Sort By:
Pageof 18
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 18, 2018
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastimJennifer M Collins, Gini F Fleming, Trevor N Christ
Gynecologic Oncology|March 30, 2010
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignanciesSarah M Temkin, S Diane Yamada, Gini F Fleming
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2022
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast CancerBarbara Pistilli, Caroline Lohrisch, Jori Sheade, et al.
Gynecologic Oncology|September 10, 2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group studyM Dwight Chen, Gini F Fleming, Suann Mitchell, et al.
Gynecologic Oncology|April 22, 2006
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group studyDeborah K Armstrong, Gini F Fleming, Maurie Markman, et al.
Gynecologic Oncology|July 10, 2020
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerationsKatherine C Kurnit, Pankti Reid, John W Moroney, et al.
Gynecologic Oncology|November 12, 2015
Chemotherapy-induced peripheral neuropathy: Current status and progressJamie R Brewer, Gladys Morrison, M Eileen Dolan, et al.
The Lancet. Oncology|December 3, 2005
Rare uterine cancersSheetal Acharya, Martee L Hensley, Anthony C Montag, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyDiane R Mould, Gini F Fleming, Kathleen M Darcy, et al.
Frontiers in Oncology|August 11, 2015
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case ReportDavid J VanderWeele, Gladell P Paner, Gini F Fleming, et al.
Pageof 18